Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Arcadia Biosciences (RKDA) Operating Expenses (2016 - 2025)

Arcadia Biosciences filings provide 12 years of Operating Expenses readings, the most recent being $2.3 million for Q4 2025.

  • On a quarterly basis, Operating Expenses fell 34.88% to $2.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $7.4 million, a 15.38% decrease, with the full-year FY2025 number at $7.4 million, down 15.36% from a year prior.
  • Operating Expenses hit $2.3 million in Q4 2025 for Arcadia Biosciences, down from $2.5 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $16.0 million in Q4 2021 to a low of -$2.0 million in Q4 2023.
  • Median Operating Expenses over the past 5 years was $3.4 million (2024), compared with a mean of $4.7 million.
  • Biggest five-year swings in Operating Expenses: skyrocketed 4812.39% in 2021 and later plummeted 136.65% in 2023.
  • Arcadia Biosciences' Operating Expenses stood at $16.0 million in 2021, then crashed by 66.18% to $5.4 million in 2022, then plummeted by 136.65% to -$2.0 million in 2023, then skyrocketed by 276.52% to $3.5 million in 2024, then crashed by 34.88% to $2.3 million in 2025.
  • The last three reported values for Operating Expenses were $2.3 million (Q4 2025), $2.5 million (Q3 2025), and $2.0 million (Q2 2025) per Business Quant data.